REGULATION OF SECRETORY PHOSPHOLIPASE A2 GROUP IIA

摘要

The invention relates to the use of secretory phospholipase A2, group IIA antagonists or inhibitors for producing a medicament for the treatment and/or prophylaxis of coronary cardiopathy, in particular stable and instable angina pectoris and acute myocardial infarction, for the prophylaxis of myocardial infarction and heart failure, hypertension and the aftereffects of arteriosclerosis, vascular diseases, renal diseases, in particular renal failure, inflammatory diseases, impaired erection and for the prevention of cardiac death.